Pharmaceutical giant acquires biopharmaceutical researcher in move to diversify beyond current blockbuster drugs. Schering-Plough shares soar 14 percent; Merck dips 7.7 percent.
|
Bill and Melinda Gates call for better tools to help women.
|
Traditionally the home turf of biotech companies, big pharma is making strides in developing new cancer drugs.
|
Whether Wyeth’s bid to become more ‘biotech’ works or not, startups will benefit.
|
An experiment reducing the level of a chemical in rats’ brains offers a promising strategy for new obesity drugs.
|
Immunizations from Merck, Glaxo against a common cause of infant mortality in the developing world succeed in clinical trials.
|
Drug maker titan to pay Progenics $60 million to jointly develop a treatment for side effects from opioid painkillers.
|
The drug maker announces on World AIDS Day it’s received a $32-million U.S. contract to develop HIV vaccine.
|
President Bush unveils a plan to prepare for a flu pandemic by strengthening the U.S. vaccine industry.
|
British pharma admits no wrongdoing but settles U.S. government’s fraudulent drug-pricing case.
|
Scientists probing the structure of these furry spiders say their study could lead to treatments for a common heart problem.
|
The first Vioxx verdict aside, analysts looking to additional indicators to gauge the power of the tidal wave coming at Merck.
|
New research suggests that low-dose contraceptive pills can double the chance of heart attack and stroke in women.
|
The top U.S. court rules in favor of allowing drug makers to use rivals’ patented drugs for research.
|
Scientists report a broad class of painkillers, including Advil and Aleve, might bring heart risks.
|
Remicade takes on Enbrel; legislation for child drug research; Pfizer’s Celebrex gets pickings from Bextra; new South African AIDS figures.
|
Wharton Biotechnology Partners and others pony up $37.3 million for Merrimack to advance in FDA arthritis trials.
|
Brand-name drug prices rise; a black box for seven anti-psychotics; Pfizer under fire; Medtronic gets an OK.
|
Viagra knock-offs have hit the pharma giant where it hurts, but it's managed a rebound, allaying investor fears and outshining its rivals.
|